Neuphoria Therapeutics Inc.
NEUP
$4.61
$0.020.44%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 118.82% | -11.51% | -178.88% | 679.54% | -141.46% |
| Total Depreciation and Amortization | 0.00% | 0.12% | 0.12% | -0.42% | 0.24% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -209.47% | 31.46% | 417.73% | 153.36% | 51.73% |
| Change in Net Operating Assets | -349.53% | -16.48% | 360.31% | -95.76% | 72.62% |
| Cash from Operations | -69.60% | -5.84% | -131.30% | 441.07% | 24.25% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 350.65% | 967.80% | -75.10% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 754.66% | 45.05% | 51.16% |
| Cash from Financing | 350.65% | 361.70% | -39.38% | 1,141.67% | 50.90% |
| Foreign Exchange rate Adjustments | 1,614.87% | -139.31% | -41.65% | 130.72% | -299.93% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,620.41% | 80.20% | -122.29% | 439.03% | 17.15% |